News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Eli Lilly and Company to Invest $150 Million in Singapore R&D Unit
March 26, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SINGAPORE, March 26 (Reuters) - Eli Lilly and Co. (LLY.N: Quote, Profile , Research) said on Monday it would invest $150 million in its existing research and development (R&D) facility in Singapore to develop drugs for cancer and diabetes.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Real estate
Asia
Eli Lilly and Company
MORE ON THIS TOPIC
Immunology and inflammation
AB Science ends 3 studies in multiple sclerosis, other immune conditions
July 13, 2026
·
2 min read
·
Tristan Manalac
Antibody-drug conjugates
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
July 10, 2026
·
1 min read
·
Gabrielle Masson
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
July 10, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
July 9, 2026
·
2 min read
·
Nick Paul Taylor
